Glenmark Pharmaceuticals has informed that it attached media release today titled ‘Glenmark Pharma is first to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes in Adults with Co-morbidities’.
The above information is a part of company’s filings submitted to BSE.